Trinity Annual Drug Index
Evaluating the Commercial Performance and Impact of Novel Drugs Approved in 2021
Home / Intelligence / Webinars / Trinity Annual Drug Index
White Paper & On-demand Webinar:
This report, the seventh in our Trinity Drug Index series, outlines key themes and emerging trends in the industry as we progress towards a new world of targeted and innovative products. We provide a comprehensive evaluation of the performance of novel drugs approved by the FDA in 2021, scoring each on its commercial performance, therapeutic value and R&D investment.
2021 saw 40 unique drug and biologic approvals, of which ~33% (13/40) were Oncology, followed by ~18% (7/40) being Autoimmune and 10% (4/40) being Neurology. In this report we describe the notable themes and trends within the industry and take a deeper look at a few products with outstanding performance. Though the impact of the COVID-19 pandemic was primarily felt in 2020, 2021 fared worse than 2020 and sustained an ongoing decline in the relationship between a product’s therapeutic value and its commercial output.
Complete the form to access the full white paper
Complete the form to view the on-demand webinar
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
This webinar will be hosted within the ON24 platform, which requires the usage of Javascript and Cookies. Please see ON24’s Privacy Policy for more information.
Webinar Speakers
Related Intelligence
White Papers
Predicting Winners: AI-Powered Portfolio Management
Can artificial intelligence and machine learning (AIML) be used to support portfolio decision-making across the life sciences industry? In this installment of our Industry Impact Series, we find that not only can the latest AIML techniques identify the drivers of success and failure in commercialization, but Trinity Life Sciences’ AI algorithm accurately predicts revenue outcomes for […]
Read More
Webinars
Launch & Learn: Trinity Launch Accelerator
Available On Demand
Today’s launch environment is fraught with greater complexity, lack of standardization and executional inefficiency. Join us for a virtual lunch and learn where experts share how Launch Accelerator enables teams to overcome launch barriers with a simple launch readiness and management process.
Watch Now
Webinars
Navigating the Early Asset Evaluation Journey with Confidence
Available On Demand
There is no room for missteps along the journey to evaluate the viability of assets in early stages of development. When making go/no go decisions, many critical questions must be answered across the early asset lifecycle. Join a team of cross-functional experts for a lively panel discussion on how to approach early commercial assessment with insight from various perspectives.
Watch Now